Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 Following Single Oral Administration in Healthy Subjects

NCT07868926 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT07868926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07868926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 Following Single Oral Administration in Healthy Subjects
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 19, 2026
Completion date
December 15, 2026
Enrollment
8 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease (adpkd)